Amarin Corp. Plc (AMRN)
13.71
+0.01
(+0.07%)
USD |
NASDAQ |
Sep 03, 16:00
13.71
0.00 (0.00%)
After-Hours: 17:01
Amarin Research and Development Expense (Annual) : 16.82M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 16.82M |
| December 31, 2024 | 17.86M |
| December 31, 2023 | 19.33M |
| December 31, 2022 | 27.30M |
| December 31, 2021 | 26.45M |
| December 31, 2020 | 37.21M |
| December 31, 2019 | 33.67M |
| December 31, 2018 | 55.14M |
| December 31, 2017 | 46.95M |
| December 31, 2016 | 48.85M |
| December 31, 2015 | 50.16M |
| December 31, 2014 | 49.48M |
| December 31, 2013 | 72.00M |
| December 31, 2012 | 58.81M |
| Date | Value |
|---|---|
| December 31, 2011 | 21.59M |
| December 31, 2010 | 28.01M |
| December 31, 2009 | 17.83M |
| December 31, 2008 | 13.12M |
| December 31, 2007 | 12.10M |
| December 31, 2006 | 15.09M |
| December 31, 2005 | 8.319M |
| December 31, 2004 | 0.979M |
| December 31, 2003 | 5.442M |
| December 31, 2002 | 5.823M |
| December 31, 2001 | 4.090M |
| December 31, 2000 | 5.817M |
| December 31, 1999 | 7.443M |
| December 31, 1998 | 1.656M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Neurocrine Biosciences, Inc. | 1.016B |
| Alkermes Plc | 318.36M |
| Cellectis SA | 75.08M |
| Akari Therapeutics Plc | 2.822M |
| Liquidia Corp. | 38.45M |